HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Visual communication among birds may also involve ritualised displays, which have developed from non-signalling actions such as preening, the adjustments of feather position, pecking, or other behaviour. These displays may signal aggression or submission or may contribute to the formation of pair-bonds. The most elaborate displays occur during courtship, where "dances" are often formed from complex combinations of many possible component movements; males' breeding success may depend on the quality of such displays. Bird calls and songs, which are produced in the syrinx, are the major means by which birds communicate with sound. This communication can be very complex; some species can operate the two sides of the syrinx independently, allowing the simultaneous production of two different songs. Calls are used for a variety of purposes, including mate attraction, evaluation of potential mates, bond formation, the claiming and maintenance of territories, the identification of other individuals (such as when parents look for chicks in colonies or when mates reunite at the start of breeding season), and the warning of other birds of potential predators, sometimes with specific information about the nature of the threat. Some birds also use mechanical sounds for auditory communication. The Coenocorypha snipes of New Zealand drive air through their feathers, woodpeckers drum for long-distance communication, and palm cockatoos use tools to drum.
Factors include reputation, nature or behaviour of customers, complex ownership, customer domicile, presence of nominee shareholders, cash-intensive businesses, use of new technologies or transactions linked to oil, tobacco, arms, precious metals or stones. Bank employees, such as tellers and customer account representatives, are trained in anti–money laundering and are instructed to report activities that they deem suspicious. Sectors subject to AML/CFT legislation are legally required to maintain internal processes capable of monitoring customers and transactions, meeting CDD and EDD obligations and identifying and reporting suspicious activities to relevant regulators and law enforcement. Financia institutions that fail to comply with these requirements face threats to their reputation and heavy fines, sometimes running into billions of dollars. Additionally, anti–money laundering software filters customer data, classifies it according to level of suspicion, and inspects it for anomalies. Such anomalies include any sudden and substantial increase in funds, a large withdrawal, or moving money to a bank secrecy jurisdiction. Smaller transactions that meet certain criteria may also be flagged as suspicious. For example, structuring can lead to flagged transactions. The software also flags names on government "blacklists" and transactions that involve countries hostile to the host nation. Once the software has mined data and flagged suspect transactions, it alerts bank management, who must then determine whether to file a report with the government.
== Research == Gene therapy is currently being studied as a possible treatment for chronic granulomatous disease. CGD is well-suited for gene therapy since it is caused by a mutation in single gene which only affects one body system (the hematopoietic system). Viruses have been used to deliver a normal gp91 gene to rats with a mutation in this gene, and subsequently the phagocytes in these rats were able to produce oxygen radicals. In 2006, two human patients with X-linked chronic granulomatous disease underwent gene therapy and blood cell precursor stem cell transplantation to their bone marrow. Both patients recovered from their CGD, clearing pre-existing infections and demonstrating increased oxidase activity in their neutrophils. However, long-term complications and efficacy of this therapy were unknown. In 2012, a 16-year-old boy with CGD was treated at the Great Ormond Street Hospital, London with an experimental gene therapy that temporarily reversed the CGD and allowed him to overcome a life-threatening lung disease. In 2024, Prime Medicine began a Phase 1/2 open-label clinical trial to evaluate PM359, an investigational gene therapy, in patients with CGD caused by NCF1 mutations. The treatment involves transplantation of autologous CD34+ stem cells modified by prime editing ex vivo. Following an announcement of preliminary results in May 2025, Prime Medicine and its clinical collaborators reported in December 2025 that two CGD patients treated with PM359 had been "effectively cured" of the disease.
Sources: en.wikipedia.org
We are more and more coming to the awful conclusion that our Ra isotopes behave not like Ra, but like Ba... Perhaps you can come up with some fantastic explanation. We ourselves realize that it can't actually burst apart into Ba. Now we want to test whether the Ac-isotopes derived from the "Ra" behave not like Ac but like La.
Any territorial authority can set up subdivisions of itself to represent specific communities, known as community or local boards. These were first established as part of the 1989 local government reforms, and are currently defined by the Local Government Act 2002. Community boards are sub-district, unincorporated local government bodies that may be established for any contiguous area in a territorial authority district. They are intended to represent and advocate for specific communities within a council catchment area. As of 2025, there are around 110 community boards across New Zealand. Local boards have greater powers than community boards. As of 2025, Auckland Council is the only territorial authority in New Zealand with local boards, which were established by the Local Government (Auckland Council) Act 2009. Auckland Council has 21 local boards covering the entire city which provide governance at the local level and are responsible for libraries and other community facilities, local parks and events, and have the power to develop local by-laws or propose local targeted rates. Each local board has 5 to 9 elected members, with 149 local board members across all boards.
=== Effects === ACE inhibitors block the conversion of angiotensin I (ATI) to angiotensin II (ATII). Arteriolar resistance is lowered, venous capacity is increased; cardiac output, cardiac index, stroke work, and volume is lowered; resistance in renal blood vessels is lowered; and lead to increased natriuresis (excretion of sodium in the urine). Bradykinin levels increase because angiotensin-converting enzyme also degrades bradykinin, and its inhibition reduces bradykinin inactivation. Under normal conditions, angiotensin II has these effects:
Sources: en.wikipedia.org
Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. It is one of the most studied sulfated polysaccharides. Heparin is a blood anticoagulant that increases the activity of antithrombin. It is used in the treatment of heart attacks and unstable angina. It can be given intravenously or by injection under the skin. Its anticoagulant properties make it useful to prevent blood clotting in blood specimen test tubes and kidney dialysis machines. Common side effects include bleeding, pain at the injection site, and low blood platelets. Serious side effects include heparin-induced thrombocytopenia. Greater care is needed in those with poor kidney function. Heparin is contraindicated for suspected cases of vaccine-induced pro-thrombotic immune thrombocytopenia (VIPIT) secondary to SARS-CoV-2 vaccination, as heparin may further increase the risk of bleeding in an anti-PF4/heparin complex autoimmune manner, in favor of alternative anticoagulant medications (such as argatroban or danaparoid). Heparin appears to be relatively safe for use during pregnancy and breastfeeding. Heparin is produced by basophils and mast cells in all mammals. The discovery of heparin was announced in 1916. It is on the World Health Organization's List of Essential Medicines. A fractionated version of heparin, known as low molecular weight heparin, is also available.
Many libraries utilize peptide chains much shorter than 70 amino acids. For 20 encoded amino acids at maximally 70 positions, this results in an upper limit of 2070, or more than 10 quindecillion (1×1091), possible combinations, not accounting for the potential use of amino acids with post-translational modifications or amino acids not encoded in the genetic code, such as selenocysteine and pyrrolysine. Peptide libraries generally encompass only a fraction of this diversity, selected for depending on the needs of the experiment, for instance keeping some amino acids constant at certain positions. Large random peptide libraries are often used for the synthesis of certain peptide molecules, such as ultra-large chemical libraries for the discovery of high-affinity peptide binders. Any increase in the library size severely affects parameters, such as the synthesis scale, the number of library members, the sequence deconvolution and peptide structure elucidation. To mitigate these technical challenges, an algorithm-supported approach to peptide library design may use molecular mass and amino acid diversity to simplify the laborious permutation identification in complex mixtures when using mass spectrometry. This approach is used to avoid mass redundancy. Biological reagent companies, such as Pepscan, ProteoGenix, Mimotopes, GenScript and many others, manufacture customized peptide libraries.
== Further reading == Ahmad, Diana L. The Opium Debate and Chinese Exclusion Laws in the Nineteenth-century American West (University of Nevada Press, 2007). Drugs and Racism in the Old West. Armero and Rapaport. The Arts of an Addiction. Qing Dynasty Opium Pipes and Accessories (privately printed, 2005) Auerbach, Sascha. Race, Law and 'The Chinese Puzzle' in Imperial Britain. New York: Palgrave-Macmillan Press, 2009. Booth, Martin. Opium: A History. London: Simon & Schuster, Ltd., 1996. Chandra, Siddharth (2008). "Economic Histories of the Opium Trade". Archived from the original on September 28, 2013. Retrieved November 9, 2008. Chouvy, P.A. (2009). "Opium. Uncovering the Politics of the Poppy, London, I.B. Tauris (Cambridge, Harvard University Press: 2010)". Archived from the original on October 26, 2011. Retrieved October 20, 2009. Day, Horace B. (1868). The Opium Habit. de Quincey, Thomas (1821). Confessions of an English opium-eater. Standard Ebooks. Derks, Hans: History of the Opium Problem: The Assault on the East, ca. 1600–1950. Sinica Leidensia, 105. Leiden: Brill, 2012. ISSN 0169-9563. ISBN 978-90-04-22158-1 Dikötter, Frank, Lars Laamann, and Zhou Xun. Narcotic culture: a history of drugs in China Chicago: University of Chicago Press, 2004. Dormandy, Thomas (2012) Opium: Reality's Dark Dream, Yale University Press Fairbank, J.K. (1978) The Cambridge History of China: volume 10 part I, Cambridge, CUP Franck Daninos, L'opium légal produit en France, La Recherche, May 2005 Great Britain (1913).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.